

Cite this: *J. Mater. Chem. B*,  
2024, 12, 8107

# Heavy-atom-free $\pi$ -twisted photosensitizers for fluorescence bioimaging and photodynamic therapy†

Dario Puchán Sánchez,<sup>‡a</sup> Korentin Morice,<sup>‡a</sup> Monika G. Mutovska,<sup>b</sup> Lhoussain Khrouz,<sup>c</sup> Pierre Josse,<sup>a</sup> Magali Allain,<sup>ib</sup> Frédéric Gohier,<sup>id</sup><sup>a</sup> Philippe Blanchard,<sup>id</sup><sup>a</sup> Cyrille Monnereau,<sup>id</sup><sup>c</sup> Tanguy Le Bahers,<sup>id</sup><sup>cd</sup> Nasim Sabouri,<sup>id</sup><sup>e</sup> Yulian Zagranyarski,<sup>\*b</sup> Clement Cabanetos<sup>id</sup><sup>\*a</sup> and Marco Deiana<sup>id</sup><sup>\*ef</sup>

As the field of preclinical research on photosensitizers (PSs) for anticancer photodynamic therapy (PDT) continues to expand, a focused effort is underway to develop agents with innovative molecular structures that offer enhanced targeting, selectivity, activation, and imaging capabilities. In this context, we introduce two new heavy-atom-free PSs, **DBXI** and **DBAI**, characterized by a twisted  $\pi$ -conjugation framework. This innovative approach enhances the spin-orbit coupling (SOC) between the singlet excited state ( $S_1$ ) and the triplet state ( $T_1$ ), resulting in improved and efficient intersystem crossing (ISC). Both PSs are highly effective in producing reactive oxygen species (ROS), including singlet oxygen and/or superoxide species. Additionally, they also demonstrate remarkably strong fluorescence emission. Indeed, in addition to providing exceptional photocytotoxicity, this emissive feature, generally lacking in other reported structures, allows for the precise monitoring of the PSs' distribution within specific cellular organelles even at nanomolar concentrations. These findings underscore the dual functionality of these PSs, serving as both fluorescent imaging probes and light-activated therapeutic agents, emphasizing their potential as versatile and multifunctional tools in the field of PDT.

Received 10th May 2024,  
Accepted 15th July 2024

DOI: 10.1039/d4tb01014k

rsc.li/materials-b

## 1. Introduction

Phototherapeutic approaches encompass a broad spectrum of medical treatments exploiting the use of light.<sup>1–4</sup> Among these approaches, photodynamic therapy (PDT) stands out as a well-established and extensively investigated method in the field of anticancer phototherapy.<sup>5–11</sup> PDT harnesses the unique attributes of photosensitizers (PSs) and light to generate highly

cytotoxic reactive oxygen species (ROS), specifically targeting cancer cells while preserving neighboring healthy tissues through minimally invasive to non-invasive modalities.<sup>12,13</sup> Upon light absorption, the PS is activated, transitioning from its ground state ( $S_0$ ) to the lowest excited singlet state ( $S_1$ ). The excited  $S_1$  state subsequently evolves into an excited triplet state ( $T_1$ ) through a phenomenon referred to as intersystem crossing (ISC). Importantly, the extended lifetime of the generated  $T_1$  state allows it to follow two distinct evolutions. It can directly generate highly cytotoxic singlet oxygen ( $^1O_2$ ) via a type-II mechanism or initiate a series of electron transfer reactions, through a type-I mechanism, resulting in the formation of radical intermediates such as superoxide ( $O_2^{\bullet-}$ ) and hydroxyl radical ( $OH^{\bullet}$ ).<sup>14</sup> These dual pathways collectively contribute to the induction of apoptosis and/or necrosis in cancer cells.<sup>6</sup>

In the context of PSs, a conventional practice has been to introduce halogens, such as Br, I, and second or third-row transition metal ions, into a target chromophore, with the aim of boosting ISC processes, via heavy atom-induced strong spin-orbit coupling (SOC).<sup>15–18</sup> However, this approach comes with certain limitations, such as inherent dark toxicity and potential high synthesis costs (in terms of price and number of

<sup>a</sup> Univ Angers, CNRS, MOLTECH-ANJOU, SFR MATRIX, F-49000 Angers, France.  
E-mail: clement.cabanetos@univ-angers.fr

<sup>b</sup> Faculty of Chemistry and Pharmacy, University of Sofia, 1 James Bourchier Blvd., 1164 Sofia, Bulgaria. E-mail: zagranyarskiyulian@gmail.com

<sup>c</sup> ENS de Lyon, CNRS, Laboratoire de Chimie UMR 5182, F-69342 Lyon, France

<sup>d</sup> Institut Universitaire de France, 5 rue Descartes, 75005 Paris, France

<sup>e</sup> Department of Medical Biochemistry and Biophysics, Umeå University, SE-901 87, Umeå, Sweden

<sup>f</sup> Institute of Advanced Materials, Faculty of Chemistry, Wrocław University of Science and Technology, 50-370 Wrocław, Poland. E-mail: m.deiana@pwr.edu.pl

† Electronic supplementary information (ESI) available: <sup>1</sup>H NMR, <sup>13</sup>C NMR, ESI-MS, X-ray. CCDC 2083069 (for **DBI**), 2335339 (for **DBXI**) and 2335340 (for **DBAI**). For ESI and crystallographic data in CIF or other electronic format see DOI:

<https://doi.org/10.1039/d4tb01014k>

‡ Contributed equally.



steps).<sup>15,19</sup> Additionally, the introduction of heavy atoms can concomitantly boost ISC from  $S_1 \rightarrow T_1$  and  $T_1 \rightarrow S_0$ , resulting in a shorter lifetime of the  $T_1$  state, potentially detrimental for the generation of ROS.<sup>15,18,20</sup>

Consequently, these concerns have significantly driven researchers' interest towards the development of heavy-atom-free PSs with optimized ISC and efficient  $T_1$  population. In recent years, three main alternative mechanisms to enhance ISC of organic PSs have been proposed which consist in:<sup>15,21</sup>

(i) Employing spin-orbit charge-transfer intersystem crossing (SOCT-ISC) by fostering, for instance, the interaction between orthogonal molecular donor-acceptor (D-A) structures.

(ii) Enhancing the SOC by involving non-bonding orbitals in the electronic transitions by replacing, for instance, the oxygen atom in the carbonyl group of conventional fluorophores with a sulfur atom.

(iii) Promoting torsional motions (twisting-induced ISC) by introducing, for instance, a nonplanar  $\pi$ -conjugated chromophore.

To date, a wide array of D-A dyads and thionated-based compounds that exhibit improved ISC have been reported, utilizing various structural frameworks such as anthracene,<sup>22,23</sup> benzothioxanthene imide,<sup>24</sup> boron dipyrromethene (BODIPY),<sup>9,20,25-28</sup> coumarin,<sup>29</sup> cyanine,<sup>30</sup> imidazolium,<sup>31</sup> naphthalimide,<sup>29,32</sup> phenoxazine,<sup>33</sup> pyrene,<sup>34</sup> perylene<sup>35,36</sup> and others.<sup>37-39</sup> Though efficient in generating ROS, such strategies have shown adverse effects on the emissive properties of these compounds, particularly in the case of thionated derivatives.<sup>24,26,32,35</sup> thus limiting their usefulness for imaging-guided PDT. Indeed, the inherent fluorescence properties of PS are crucial for several reasons.<sup>40</sup> They enable real-time tumor visualization, allowing precise boundary delineation for accurate targeting and comprehensive treatment.<sup>41-44</sup> Fluorescence aids in monitoring PS distribution and concentration within the tissue, ensuring adequate tumor accumulation before activation.<sup>41-44</sup> This selective activation minimizes damage to healthy tissues, enhancing treatment safety and effectiveness. Additionally, fluorescent imaging is essential for dosimetry, determining the appropriate light dose for effective PDT without excessive damage.<sup>45</sup> Post-treatment, fluorescence imaging assesses therapy response by evaluating signal changes, guiding further therapeutic decisions.<sup>46,47</sup> This advancement facilitates precise delineation of the treatment area and enables continuous monitoring of therapeutic progress.

Moreover, PSs derived from thiones are prone to oxidation when exposed to light, leading to structural alterations. This raises safety concerns regarding their suitability for potential clinical applications.<sup>24</sup>

In contrast to these design principles, there has been a recent significant focus on the exploration of heavy-atom-free PSs that incorporate a twisted  $\pi$ -conjugated system.<sup>15</sup> Indeed, considerable research efforts have been directed towards investigating the photophysical properties of extended  $\pi$ -conjugated helicoidal systems, which includes triply linked bay-fused diperylene bisimides,<sup>48</sup> chromophores derived from

hexa-*peri*-hexabenzocoronenes,<sup>49</sup> phenanthrene-fused twisted perylenebisimide<sup>50</sup> and BODIPY<sup>51-53</sup> derivatives. However, despite their promise, these materials have primarily been restricted to test tubes, with only few practical applications in cellular models.<sup>52,53</sup> Furthermore, they present several drawbacks such as their intricate synthesis, high molecular weight, limited fluorescence quantum yield ( $\Phi_F$ ), and, for some of them, a weak absorbance in the visible spectral range (above 400 nm).<sup>15,54</sup>

Drawing on this, we reported on a rational design of a dibenzothioxanthene imide, abbreviated as **DBI**,<sup>55</sup> stemming from a classic highly luminescent dye, initially reported in the late 1970's for plastic staining and textile industry, namely the benzothioxanthene imide (**BTI**). Characterized by a distorted  $\pi$ -conjugated core, resulting from the selective inclusion of an extra fused phenyl ring, that facilitates efficient ISC through a significant SOC, **DBI** demonstrated remarkable ROS production and phototherapeutic efficacy at nanomolar concentrations. However, although it remains fluorescent, its  $\Phi_F$  of *ca.* 8%, was found to be at the lower limit for efficient detection and localization of *in vivo* tumor accumulation, a key feature for therapy-guiding PSs.<sup>55</sup>

To overcome this obstacle, and provide a second generation of **DBI**-related molecules that attain simultaneously high fluorescence emission and effective ROS generation, we herein present derivatives, named **DBXI** and **DBAI** in which the sulfur heteroatom bridging the upper and lower part of the molecules was selectively replaced by either a less bulky chalcogen (O) or an unsubstituted amine, thus strongly affecting (i) the molecular strain, and thereby, (ii) the distortion induced SOC thus above all (iii) their relevant spectroscopic properties. By conducting a comprehensive examination that incorporates experimental, theoretical, and biological investigations, we thoroughly scrutinized the photophysical and *in cellulo* properties of these newly synthesized PSs, yielding highly consistent findings. With a strong visible centered emission, these compounds can be readily monitored in real-time, disclosing their accumulation within specific cellular organelles. Moreover, these PSs display minimal dark toxicity and efficiently inhibit cell proliferation in a dose-dependent manner with a half-maximum inhibitory concentration ( $IC_{50}$ ) in the nanomolar range ( $\sim 100$  nM) upon light exposure associated to morphological changes in cells, leading to apoptosis. This study further highlights the key role of molecular design and promising applications of such new generation of  $\pi$ -distorted heavy-atom-free small PSs for imaging-guided photodynamic cancer treatment.

## 2. Experimental

### Synthetic procedures and compounds characterization

All reagents and chemicals from commercial sources were used without further purification unless specified. Solvents were dried and purified using standard techniques. Flash chromatography was performed with analytical-grade solvents using



Aldrich silica gel (technical grade, pore size 60 Å, 230–400 mesh particle size). Flexible plates Alugram Xtra SIL G UV254 from Macherey-Nagel were used for thin layer chromatography (TLC). Compounds were detected by ultraviolet (UV) irradiation (Bioblock Scientific). Nuclear magnetic resonance (NMR) spectra were recorded with a Bruker Avance III 300 ( $^1\text{H}$ , 300 MHz and  $^{13}\text{C}$ , 76 MHz) or a Bruker Avance DRX500 ( $^1\text{H}$ , 500 MHz and  $^{13}\text{C}$ , 125 MHz). Chemical shifts are given in ppm relative to the residual  $^1\text{H}$  resonance of the deuterated solvent and coupling constants  $J$  in Hz. High-resolution mass spectrometry (HRMS) was performed with a JEOL JMS-700 B/E. Matrix Assisted Laser desorption/ionization was performed on MALDI-TOF MS BIFLEX III Bruker Daltonics spectrometer using *trans*-2-[3-(4-*tert*-butylphenyl)-2-methyl-2-propenylidene]malononitrile (DCTB+) as matrix (Bruker, Billerica, MA, USA). The purity of the final compounds was >95% as assessed by NMR, HRMS (mass accuracy <5 ppm) and X-ray diffraction.

**6-(2-Methoxynaphthalen-1-yl)-2-(pentan-3-yl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (2).** In a Schlenk tube, **1** (500 mg, 1.44 mmol) was added to (2-methoxynaphthalen-1-yl)boronic acid (875 mg, 4.33 mmol), sodium carbonate (459 mg, 4.33 mmol) and  $\text{Pd}(\text{PPh}_3)_4$  (83 mg, 0.07 mmol). After vacuum pumping and flushing with argon ( $3 \times 10$  minutes), THF (40 mL) flushed with argon was added and the mixture was heated at 95 °C overnight. After completion of the reaction, the solvent was evaporated and the mixture was dissolved in  $\text{CH}_2\text{Cl}_2$  for purification by silica-gel column chromatography (eluent:  $\text{CH}_2\text{Cl}_2$ ) to afford **2** as a green oil (562 mg, 92% yield).  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.70 (d,  $J = 7.5$  Hz, 1H), 8.57 (d,  $J = 7.2$  Hz, 1H), 8.05 (d,  $J = 9.1$  Hz, 1H), 7.90 (d, 1H), 7.73–7.66 (m, 2H), 7.54 (dd,  $J = 8.4, 7.2$  Hz, 1H), 7.47 (d,  $J = 9.1$  Hz, 1H), 7.37 (ddd,  $J = 8.1, 6.8, 1.3$  Hz, 1H), 7.27 (dd, 1H), 7.09 (dd, 1H), 5.11 (td,  $J = 15.5, 9.8, 5.9$  Hz, 1H), 3.79 (s, 3H), 2.36–2.23 (m, 2H), 2.02–1.87 (m, 2H), 0.95 (t,  $J = 7.5$  Hz, 6H).  $^{13}\text{C}$  NMR (76 MHz,  $\text{CDCl}_3$ )  $\delta$  154.51, 141.98, 133.78, 132.50, 131.42, 130.71, 129.88, 129.04, 128.89, 128.22, 127.15, 126.89, 124.93, 124.03, 121.02, 113.35, 57.48, 56.66, 56.62, 25.24, 11.50. HRMS (MALDI-TOF):  $m/z$  calculated for  $\text{C}_{28}\text{H}_{25}\text{NO}_3$ : 423.1843, found: 423.1840 ( $s = 0.69$  ppm).

**6-(2-Hydroxynaphthalen-1-yl)-2-(pentan-3-yl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (3).** In a Schlenk tube, **2** (500 mg, 1.18 mmol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (30 mL), put at 0 °C and degassed with argon. After 15 minutes, a 1 M solution of  $\text{BBr}_3$  in  $\text{CH}_2\text{Cl}_2$  (3.54 mL, 3.54 mmol) was added dropwise and the solution turned dark. After 10 minutes of stirring, the reaction was allowed back to room temperature and stirred overnight as the color became progressively clearer. After completion of the reaction, the mixture was treated with an aqueous solution saturated of  $\text{NaHCO}_3$  and extracted with  $\text{CH}_2\text{Cl}_2$ . The solvent was evaporated and the crude was dissolved in  $\text{CH}_2\text{Cl}_2$  for purification by silica-gel column chromatography (eluent:  $\text{CH}_2\text{Cl}_2/\text{EtOAc}$  9/1) to afford **3** as a green oil (458 mg, 95% yield).  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.74 (d,  $J = 7.4$  Hz, 1H), 8.61 (d,  $J = 7.1$  Hz, 1H), 7.96 (d,  $J = 8.9$  Hz, 1H), 7.89 (d,  $J = 8.1$  Hz, 1H), 7.82 (d,  $J = 7.4$  Hz, 1H), 7.76 (dd,  $J = 8.5, 1.2$  Hz, 1H), 7.60 (dd,  $J = 8.4, 7.2$  Hz, 1H), 7.40–7.27 (m, 3H), 7.05 (d,  $J = 8.4$  Hz,

1H), 5.10 (td, 1H), 4.92 (s, 1H), 2.36–2.21 (m, 2H), 2.02–1.86 (m, 2H), 0.94 (t,  $J = 7.4$  Hz, 6H).  $^{13}\text{C}$  NMR (76 MHz,  $\text{CDCl}_3$ )  $\delta$  151.25, 140.24, 133.72, 132.43, 131.38, 130.81, 130.54, 129.05, 128.95, 128.30, 127.46, 127.16, 124.57, 123.80, 117.98, 117.52, 57.64, 25.10, 11.40. HRMS (MALDI-TOF):  $m/z$  calculated for  $\text{C}_{27}\text{H}_{23}\text{NO}_3$ : 408.1602, found: 408.1605 ( $\Delta = -0.82$  ppm).

**2-(Pentan-3-yl)-1H-benzo[7,8]xantheno[2,1,9-def]isoquinoline-1,3(2H)-dione (DBXI).** **3** (250 mg, 0.61 mmol) and  $\text{K}_2\text{CO}_3$  (337 mg, 2.44 mmol) were degassed and flushed with argon ( $3 \times 10$  minutes) in a 20 mL microwave vial. Argon flushed nitrobenzene (20 mL) was added and the mixture was stirred at 200 °C under microwaves for 40 h. The resulting crude was cooled down and put directly in a silica-gel column (eluent:  $\text{CH}_2\text{Cl}_2$ /petroleum ether 4/6 to remove most of nitrobenzene, then 6/4 to collect the product). The solvent was then evaporated to afford **DBXI** as an orange solid (135 mg, 54% yield).  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.76 (d,  $J = 8.6, 0.9$  Hz, 1H), 8.51 (d,  $J = 8.1$  Hz, 1H), 8.46 (d,  $J = 8.3$  Hz, 1H), 8.33 (dd,  $J = 8.1, 0.6$  Hz, 1H), 7.85–7.77 (m, 2H), 7.58 (ddd,  $J = 8.6, 6.9, 1.5$  Hz, 1H), 7.47 (ddd,  $J = 8.0, 6.9, 1.1$  Hz, 1H), 7.31 (d,  $J = 8.9$  Hz, 1H), 7.16 (d,  $J = 8.4$  Hz, 1H), 5.03 (td,  $J = 9.5, 5.9$  Hz, 1H), 2.31–2.10 (m, 2H), 1.96–1.76 (m, 2H), 0.85 (t,  $J = 7.5$  Hz, 6H).  $^{13}\text{C}$  NMR (76 MHz,  $\text{CDCl}_3$ )  $\delta$  155.26, 152.53, 133.88, 133.35, 131.83, 130.36, 129.59, 128.39, 125.95, 124.18, 120.78, 119.31, 117.78, 113.63, 109.43, 57.39, 25.13. HRMS (MALDI-TOF):  $m/z$  calculated for  $\text{C}_{27}\text{H}_{21}\text{NO}_3$ : 407.1523, found: 407.1516 ( $\Delta = 1.69$  ppm).

**6-Bromo-7-nitro-2-(pentan-3-yl)-1H-benzo[de]isoquinoline-1,3(2E)-dione (5).** To a suspension of **4** (500 mg, 1.55 mmol) in 2 mL of NMP was added dropwise a solution of 3-aminopentane (0.51 mL, 3.1 mmol) in 1.33 mL of acetic acid. The mixture was heated at 120 °C for 20 minutes. Then the reaction was poured into water and extracted with  $\text{CH}_2\text{Cl}_2$  ( $3 \times 15$  mL). The organic phase was dried over  $\text{MgSO}_4$  and evaporated. The product was purified by column chromatography (eluent:  $\text{CH}_2\text{Cl}_2$ /petroleum ether 8/2) to afford **5** as a pale brown powder was obtained (334 mg, 54% yield).  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.68 (d,  $J = 7.9$  Hz, 1H), 8.50 (d,  $J = 8.0$  Hz, 1H), 8.21 (d,  $J = 8.0$  Hz, 1H), 7.92 (d,  $J = 7.9$  Hz, 1H), 5.07–4.91 (m, 1H), 2.31–2.10 (m, 2H), 2.01–1.81 (m, 2H), 0.89 (t,  $J = 7.5$  Hz, 6H).

**6-(Naphthalen-1-yl)-7-nitro-2-(pentan-3-yl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (6).** Argon flushed 1,4-dioxane (3.1 mL) and water (0.75 mL) were added over a mixture of **4** (300 mg, 0.77 mmol), 1-naphthylboronic acid (198 mg, 1.15 mmol), potassium carbonate (318 mg, 2.3 mmol) and  $\text{Pd}(\text{PPh}_3)_4$  (44 mg, 0.04 mmol) in a sealed tube under argon. The reaction mixture was stirred at 110 °C for 6 h and monitored by TLC (eluent:  $\text{CH}_2\text{Cl}_2$ ). The reaction was cooled at room temperature and extracted with water and  $\text{CH}_2\text{Cl}_2$ . The organic phase was collected and dried over  $\text{MgSO}_4$  and the solvent was evaporated. The resulting product was purified by column chromatography (eluent:  $\text{CH}_2\text{Cl}_2$ ) to obtain **5** as a yellow-orange powder (310 mg, 92% yield).  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  8.78 (d,  $J = 7.6$  Hz, 1H), 8.68 (d,  $J = 7.8$  Hz, 1H), 8.22–7.88 (m, 3H), 7.84 (d,  $J = 7.8$  Hz, 1H), 7.64 (d,  $J = 8.4$  Hz, 1H), 7.60–7.51 (m, 1H), 7.50–7.37 (m, 2H), 7.25 (m, 1H), 5.68–4.57 (m, 1H), 2.65–2.13 (m, 2H), 2.13–1.77 (m, 2H), 0.95



( $t, J = 7.5$  Hz, 6H).  $^{13}\text{C}$  NMR (76 MHz,  $\text{CDCl}_3$ ) 152.1, 142.4, 135.5, 133.9, 133.6, 131.4, 130.5, 129.7, 128.7, 127.3, 127.0, 126.5, 125.3, 124.8, 123.3, 122.6, 58.2, 25.1, 11.5. HRMS (MALDI-TOF)  $m/z$  calculated for  $\text{C}_{27}\text{H}_{22}\text{N}_2\text{O}_4$ : 438.1589, found 438.1585 ( $\Delta = 0.88$  ppm).

**2-(Pentan-3-yl)benzo[*lmn*]naphtho[2,1-*c*][2,8]phenanthroline-1,3(2*H*,6*H*)-dione (DBAI).** Argon flushed 1,2-dichlorobenzene (7 mL) was added to a mixture of **2** (250 mg, 0.57 mmol) and triphenylphosphine (449 mg, 1.7 mmol) in a sealed tube under argon. The mixture was stirred for 7 h at reflux. The mixture was cooled down to room temperature and was directly injected on a silica-gel chromatographic column (eluent:  $\text{CH}_2\text{Cl}_2/\text{EtOAc}$ ). A red powder was obtained (yield 91%, 210 mg).  $^1\text{H}$  NMR (300 MHz,  $\text{DMSO-}d_6$ )  $\delta$ : 12.29 (s, 1H), 9.00 (d,  $J = 8.6$  Hz, 1H), 8.43 (t,  $J = 6.8$  Hz, 2H), 8.31 (d,  $J = 8.5$  Hz, 1H), 8.09 (d,  $J = 8.9$  Hz, 1H), 8.03 (d,  $J = 8.0$  Hz, 1H), 7.77–7.66 (m, 1H), 7.66–7.38 (m, 2H), 7.08 (d,  $J = 8.4$  Hz, 1H), 5.79–4.51 (m, 1H), 2.29–2.05 (m, 2H), 1.89–1.74 (m, 2H), 0.78 (t,  $J = 7.4$  Hz, 6H).  $^{13}\text{C}$  NMR (126 MHz,  $\text{DMSO-}d_6$ )  $\delta$  170.3, 142.9, 138.4, 137.7, 133.2, 131.2, 130.6, 129.9, 129.4, 128.8, 128.1, 125.3, 123.2, 122.2, 117.4, 116.9, 112.3, 105.7, 79.2, 59.7, 55.6, 24.3, 20.8, 14.1, 11.2. HRMS (MALDI-TOF)  $m/z$  calculated for  $\text{C}_{27}\text{H}_{22}\text{N}_2\text{O}_2$  406.16763, found 406.16758 ( $\Delta = 0.11$  ppm).

### Crystallographic data

Crystal data were collected on a Rigaku Oxford Diffraction SuperNova diffractometer equipped with an Atlas CCD detector and micro-focus Cu-K $\alpha$  radiation ( $\lambda = 1.54184$  Å). The structures were solved by dual-space algorithm and refined on F2 by full matrix least-squares techniques using SHELX package (G.M. Sheldrick, ShelXT2018/2, ShelXL2018/3-2019/3). All non-hydrogen atoms were refined anisotropically and the H atoms were included in the calculation without refinement. Multiscan empirical absorption was corrected for **DBI** and **DBAI** by using CrysAlisPro program (CrysAlisPro, Rigaku Oxford Diffraction, 2019–2023). Gaussian absorption corrections were applied for **DBXI**. Deposition number(s) 2083069 (for **DBI**), 2335339 (for **DBXI**) and 2335340 (for **DBAI**) contain(s) the supplementary crystallographic data for this paper.†

### Photophysical characterization

Absorption spectra were obtained using a Jasco V-650 spectrophotometer for diluted solutions ( $\sim 10$  or  $1$   $\mu\text{M}$ ), employing spectrophotometric grade solvents. Fluorescence spectra were acquired with a Horiba Jobin Yvon Fluorolog-3. Steady-state luminescence measurements utilized unpolarized light from a 450 W xenon continuous wave lamp as the light source, with luminescence detected at a  $90^\circ$  angle. These measurements were conducted in diluted solutions within a 10 mm Hellma quartz cuvette, employing a Hamamatsu R928 detector for visible light and a liquid nitrogen-cooled, solid-state Indium Gallium Arsenide detector (850–1600 nm) for near-infrared measurements of singlet oxygen phosphorescence signals. Spectra corrections accounted for variations in the excitation source light intensity and emission spectral responses.

$\Phi_{\text{F}}$  were determined in diluted chloroform ( $\text{CHCl}_3$ ) solutions with an absorbance below 0.1, using the following

equation for approximation:

$$\frac{\varphi_{\text{f}(x)}}{\varphi_{\text{f}(r)}} = \frac{A_r}{A_x} \times \frac{n_x^2}{n_r^2} \times \frac{D_x}{D_r} \quad (1)$$

where  $A$  represents the absorbance (or optical density) at the excitation wavelength,  $n$  is the refractive index of the solvent, and  $D$  is the integrated luminescence intensity, with “ $r$ ” and “ $x$ ” denoting the reference and sample, respectively. The reference compound was coumarin-153 in methanol ( $\Phi_{\text{F}} = 0.45$ ). The excitation of both reference and sample compounds was ideally at the same wavelength. The results reported are the averages of 4–5 independent measurements at various absorbances (ranging from 0.01–0.1) for both the sample and reference. A linearization process was applied to derive an average value with a high coefficient of determination  $R^2 > 0.99$ . Singlet oxygen quantum yield ( $\Phi_{\Delta}$ ) determinations followed the same methodology, with the exception that  $\text{CDCl}_3$  was consistently used as the solvent (with  $n_x = n_r$ ).  $^1\text{O}_2$  emission was monitored at  $\sim 1270$  nm. Phenalenone ( $\Phi_{\Delta} = 0.95$ ) served as the reference compound in these measurements.

### EPR experiments

5,5-Dimethyl-1-pyrroline *N*-oxide (DMPO) was purchased from TCI Chemicals. All samples were prepared under air atmosphere using capillary tubes filled with  $1 \times 10^{-4}$  M solutions of each chromophore with  $5 \times 10^{-3}$  M of the spin trap in DMSO. The irradiations were conducted using a Thorlab LED with a wavelength of 455 nm, which was directly aimed into the EPR cavity during the recording of the spectrum. All EPR assays were performed at room temperature, utilizing a Bruker E500 spectrometer that operated at the X-band frequency of 9.44 GHz, equipped with a standard cavity and a modulation frequency of 100 kHz. The settings of the instrument were adjusted as follows: microwave power at 2–2–69 mW and modulation amplitude at 1 G. The hyperfine coupling constants, including  $a$  and  $g$  values, were determined through the simulation of experimental spectra using the EasySpin toolbox in Matlab.

### Computational data

The Gaussian16 code<sup>56</sup> was used to optimize the geometries at the ground and excited states along with the global hybrid functional PBE0.<sup>57</sup> This functional was chosen because of its accuracy to reproduce spectroscopic properties of these molecules. Structural optimizations and subsequent frequency calculations for both the ground and excited states were performed using an all electron Pople triple zeta basis set with one polarization function on all atoms and one diffuse function of heavier atoms, known as 6–311+G(d,p), for H, C, N, O and S atoms. Bulk solvent effects were included using the polarizable continuum Model (PCM) of Tomasi and co-workers.<sup>58</sup> Default radii (from the UFF, scaled by 1.1) were used. Excited state geometry was obtained by minimizing the forces of the  $S_1$  state computed at the TD-DFT level by considering the 3 first excited states. The Orca program<sup>59</sup> was used to compute the SOC between the three first triplet states (namely  $T_1$  and  $T_2$ ) and



the  $S_1$  state at the  $S_1$  optimized geometry using the quadruple-response Tamm–Dancoff approximation of TD-DFT at the PBE0/PCM level with the Def2-TZVP basis set adapted for the Douglas–Kroll calculations. The spin–orbit coupling was computed using the Douglas–Kroll Hamiltonian along with the spin–orbit mean field approach.

### Live cell imaging

The day prior to treatment, a total of  $10 \times 10^4$  HeLa cells were plated on a glass-bottom microwell dish (MatTek Corp.) in DMEM medium enriched with  $1 \times$  penicillin–streptomycin and 10% fetal bovine serum, and they were maintained at  $37^\circ\text{C}$  in a 5%  $\text{CO}_2$  environment. HeLa cells were washed with DMEM medium (twice), and then treated with **DBXI** (500 nM) or **DBAI** (500 nM) for 24 hours. After that, the cells were washed twice with  $1 \times$  phosphate-buffered saline (PBS) before being incubated with the organelle-selective stains. Nuclear staining was accomplished using Hoechst 33342 (500 nM; Sigma-Aldrich, ref. no.: B2261), while ER-Tracker™ Red (500 nM; ThermoFisher Scientific, ref. no.: E34250), Lyso-Tracker™ Red (100 nM; ThermoFisher Scientific, ref. no.: L7528), or Mito-Tracker™ Red (100 nM; ThermoFisher Scientific, ref. no.: M7512) were utilized for organelle-specific staining. These dyes were dissolved in a live cell imaging solution (Molecular Probes™, ref. no.: A14291DJ) and incubated with the cells for 30 minutes at  $37^\circ\text{C}$  in a 5%  $\text{CO}_2$  environment. Before imaging, the cells were washed twice with the live cell imaging solution.

Imaging was conducted using a Leica SP8 FALCON confocal microscope equipped with an incubation chamber set to  $37^\circ\text{C}$  and 5%  $\text{CO}_2$ . Maximum intensity projections of Z-stack images were generated for data presentation. All data were subsequently processed using ImageJ software.

### Intracellular detection of ROS

The day prior to treatment,  $10 \times 10^4$  HeLa cells were cultured on glass-bottom microwell dishes (MatTek Corp.). Subsequently, these cells were exposed to **DBXI** (500 nM), **DBAI** (500 nM) or an equivalent volume of DMSO (0.04% v/v) and then incubated at  $37^\circ\text{C}$  in 5%  $\text{CO}_2$  for 24 hours. Then, the cells were exposed to CellROX™ green reagent (5  $\mu\text{M}$ ; ThermoFisher Scientific, ref. no.: C10444) and Hoechst 33258 (500 nM) dissolved in the live cell imaging solution, and incubated at  $37^\circ\text{C}$  for 30 minutes. Subsequently, the cells were imaged at two time points: before irradiation and 5 minutes post-irradiation, using a 480 nm supercontinuum white light laser (WLL) operating at 80% for a duration of 5 minutes.

### Phototoxic experiments

HeLa cells, at a density of  $5 \times 10^3$  cells per well, were placed onto 96-well plates a day prior to the treatment with **DBXI** or **DBAI**. **DBXI** or **DBAI** were dissolved in complete medium at different concentrations, with DMSO reaching a maximum value of 0.5% v/v, and subsequently added to the cells for 24 hours. Where indicated, the cells underwent photo-irradiation using the EVOS® FL cell imaging system equipped with a customizable LED cube (Invitrogen, ref. no.: AMEP4651;

excitation: 470/22 nm) operating at  $27 \text{ mW cm}^{-2}$  for 6 minutes. Following photo-irradiation, the cells were further incubated for 24 hours at  $37^\circ\text{C}$  in a 5%  $\text{CO}_2$  atmosphere. After 48 hours from the initiation of **DBXI** or **DBAI** treatment, PrestoBlue™ (Invitrogen, ref. no.: A13261) was introduced to each well, and the cells were incubated at  $37^\circ\text{C}$  in 5%  $\text{CO}_2$  for an additional three hours. The assessment of cell viability was performed by measuring the fluorescence signal emitted by PrestoBlue ( $\lambda_{\text{exc}}/\lambda_{\text{em}}$ : 560/590 nm) using a Synergy H4 microplate reader (Biotek).

The photo-induced cell death caused by **DBXI** was corroborated using the LIVE/DEAD™ viability/cytotoxicity kit (Invitrogen, ref. no.: L34960). Cells were plated on glass-bottom microwell dishes (MatTek Corp.) a day prior to treatment. HeLa cells received a treatment of **DBXI** (500 nM) or an equivalent volume of DMSO and were then incubated at  $37^\circ\text{C}$  in a 5%  $\text{CO}_2$  atmosphere for 24 hours. Where necessary, the cells underwent photo-irradiation. Following this, an additional 24-hour incubation at  $37^\circ\text{C}$  in 5%  $\text{CO}_2$  was conducted. 48 hours post-**DBXI** treatment, live/dead fixable red stain ( $1 \mu\text{L mL}^{-1}$ ) was applied to the cells for 30 minutes at  $37^\circ\text{C}$  before fixation with 4% paraformaldehyde (PFA). Prior to imaging, cells were washed with  $1 \times$  PBS enhanced with 1% bovine serum albumin. Imaging was performed using a Leica SP8 FALCON confocal microscope, employing maximum intensity projection of Z-stack images for data representation. ImageJ software was utilized for all data processing.


### Morphological changes associated with light irradiation and PSs treatment

24 hours prior to **DBXI** or **DBAI** treatment,  $5 \times 10^3$  cells per well were seeded in complete medium on 96-well plates. **DBXI** or **DBAI**, at a concentration of  $1 \mu\text{M}$ , or an equivalent volume of DMSO (0.08% v/v), were dissolved in complete medium and added to the cells for an additional 24 hours at  $37^\circ\text{C}$  in a 5%  $\text{CO}_2$  environment. Subsequently, the cells were subjected to photo-irradiation using the EVOS® FL cell imaging system equipped with adjustable-intensity LED cubes (excitation = 470/22 nm operating at  $30 \text{ mW cm}^{-2}$ ).

## 3. Results and discussion

### Molecular design and synthesis

The synthetic route initially engineered for the synthesis **DBI** had to be entirely redesigned for the preparation of the new



Scheme 1 Synthetic routes and chemical structures of **DBXI** (top) and **DBAI** (bottom).



target derivatives. Starting with the oxo derivative, preparation of the latter was initiated by reacting the bromonaphthalimide **1** with the commercially available (2-methoxynaphthalen-1-yl) boronic acid **2** under Suzuki–Miyaura coupling conditions. The methoxy group of the resulting intermediate **3** was then deprotected with  $\text{BBr}_3$  prior to ring close the system under basic conditions to afford the desired **DBXI** derivative (Scheme 1).

Regarding its NH counterpart, a different approach was developed, relying on the use of the 4-bromo-5-nitro-1,8-naphthalic anhydride. Starting with its imidization in presence of the 3-aminopentane, the resulting intermediate **6** was thereafter engaged in a Suzuki–Miyaura cross coupling reaction with the commercial 1-naphthaleneboronic acid **7** to afford **8**. Finally, **8** was cyclized under Cadogan conditions providing the desired **DBAI** compound.

The structures of both **DBXI** and **DBAI** were investigated using NMR spectroscopy and HRMS (Fig. S1–S16, ESI<sup>†</sup>). These data were confirmed through X-ray diffraction performed on crystals grown using the slow evaporation technique (Table S1, ESI<sup>†</sup> and experimental section for details).

Both molecules exhibited overall good solubility in common organic solvents, with **DBAI** outperforming **DBXI**, facilitating the investigation of their spectroscopic and photophysical properties.

### Photophysical properties

The absorption and emission spectra of **DBXI** and **DBAI** were recorded in  $\text{CHCl}_3$  and compared with those of the parent **DBI** compound (Fig. 1). This revealed a significant impact of the substituent change on the spectral shape and the position of the maxima within the series (Fig. 1). Whereas the parent **DBI** exhibited structureless absorption and emission bands, with a maximum absorption ( $\lambda_{\text{max}}$ ) at 481 nm and maximum emission ( $\lambda_{\text{em}}$ ) at 544 nm, the two new compounds displayed notable differences. Both **DBXI** and **DBAI** had absorption and emission profiles characterized by pronounced vibronic progressions, indicating a more localized character of the  $\pi$ - $\pi^*$  transition as typically observed in closely related naphthalene diimide molecules. Specifically, **DBXI** exhibited a notable blue shift, with  $\lambda_{\text{max}}$  at 447 and 472 nm and  $\lambda_{\text{em}}$  at 494 nm, compared to **DBI**. Conversely, the spectral maxima of **DBAI** ( $\lambda_{\text{max}} = 487$  and 517 nm and  $\lambda_{\text{em}} = 543$  nm) were very similar to those of the parent **DBI**. Additionally, **DBAI** demonstrated a minor




Fig. 1 Absorption and emission spectra of 10  $\mu\text{M}$   $\text{CHCl}_3$  solutions of **DBAI**, **DBXI**, and **DBI**.  $\lambda_{\text{exc}}$  (**DBAI**) = 480 nm,  $\lambda_{\text{exc}}$  (**DBXI**) = 446 nm and  $\lambda_{\text{exc}}$  (**DBI**) = 480 nm.




Fig. 2 Summary of TD-DFT calculations for (A) **DBAI**, (B) **DBXI** and (C) **DBI**. Variation of the electron density,  $\Delta\rho$ , presenting the electron density depletion and the electron increase in blue and green respectively (iso-value 0.004 a.u.) as long as the extract  $D_{\text{CT}}$  index. Jablonski diagram is presented with  $S_0$ ,  $S_1$  and  $T_n$  levels in black, blue and green respectively. The torsion angle of the  $\pi$ -systems is presented in inset.






Fig. 3 EPR signal of a solution of **DBAI** and DMPO in DMSO under 455 nm irradiation. Experimental (blue) and simulated (red) spectra of DMPO superoxide adduct.  $g = 2.006$ ,  $a_N = 12.85$  G,  $a_H = 10.37$  G,  $a_H = 1.28$  G.

transition of low intensity with a similar band structure, peaking at 420 nm.

This evolution was corroborated by vertical transition energies computed at the TD-DFT level, which yielded absorption

wavelengths of 461 nm for **DBAI**, 436 nm for **DBXI**, and 470 nm for **DBI**, along with emission wavelengths of 527 nm for **DBAI**, 506 nm for **DBXI**, and 545 nm for **DBI**. The more localized character of the electronic transition was further confirmed by the computation of the  $D_{CT}$  index, which is related to the variation in electron density between the ground and excited states and quantifies the strength of a charge transfer transition. The later was found to be larger for **DBI** than for **DBXI** and **DBAI**, indicating a stronger charge transfer transition in **DBI** as illustrated in Fig. 2.<sup>60,61</sup>

The most striking effects of changing the bridging heteroatom were observed in the photophysical properties of the molecule. While **DBI** exhibited very efficient intersystem crossing (ISC), with  $\Phi_{\Delta}$  of approximately 0.95 and minimal residual luminescence, the ISC efficiency was significantly reduced for **DBXI** and **DBAI** to  $\Phi_{\Delta}$  values of *ca* 0.21 and 0.33, respectively. As an antagonistic effect, the  $\Phi_F$  significantly increased to 0.68 for **DBXI** and up to 0.72 for **DBAI**, associated to fluorescence lifetimes of 4.95 ns for **DBXI** and 6.7 ns for **DBAI**. Quantum chemical calculations provided atomistic insights into these observations. The ISC, responsible for populating the triplet state necessary for generating  $^1O_2$ , is still promoted by SOC




Fig. 4 Cellular localization of **DBXI** and **DBAI**. CLSM images of live HeLa cells treated with **DBXI** (500 nM, green signal) (A) or **DBAI** (500 nM, green signal) (B) and incubated for 24 hours. After 24 hours, the cells were co-stained with the nuclear dye Hoechst 33342 (500 nM, blue signal) and Lyso-Tracker Red (100 nM, red signal). 2D scatter diagrams depicting **DBXI** or **DBAI** and Lyso-Tracker Red channels are presented, and the quantification of colocalization has been accomplished using the Pearson correlation coefficient (PCC). Image settings:  $\lambda_{exc}/\lambda_{em}$ : 405/420–470 nm for Hoechst;  $\lambda_{exc}/\lambda_{em}$ : 480/495–560 nm for **DBXI** or **DBAI**;  $\lambda_{exc}/\lambda_{em}$ : 577/600–710 nm for Lyso-Tracker Red. The scale bar is set at 25  $\mu$ m for regular images (top panel) and 10  $\mu$ m for the enlarged images (bottom panel; indicated zoom).



resulting from the distortion of the  $\pi$ -systems, also referred to as the twisting induced triplet state population. This distortion was computed for all three molecules (Fig. 2) and observed experimentally from X-ray structures. As expected, this effect was more pronounced for **DBI** than for **DBAI** and **DBXI** as characterized by the largest dihedral angle (by more than  $10^\circ$ ) measured between the upper and lower naphthyl rings (Fig. 2). This feature is directly related to the higher SOC computed for **DBI**, compared to the other two molecules, and ultimately the variations in  $^1\text{O}_2$  production efficiency that were experimentally evaluated.

To determine if, beyond a type-II mechanism driven by  $^1\text{O}_2$ , a type-I mechanism could also play a role in generating ROS, electron paramagnetic resonance (EPR) experiments were conducted on both **DBAI** and **DBXI**. Utilizing 5,5-dimethyl-1-pyrroline *N*-oxide (DMPO) as a radical scavenger, capable of reacting with  $\text{O}_2^{\cdot-}$ , no radical adducts were detected for **DBXI**. In contrast, **DBAI** exhibited a well-resolved hyperfine splitting structure, indicative of a DMPO-superoxide adduct signal, corroborated by simulated EPR spectra (Fig. 3). These findings suggest that the photocytotoxic potential of these compounds might be exclusively mediated through a type-II mechanism for

**DBXI**, while **DBAI** could involve a combined type-I and type-II mechanism.

### Live cells fluorescence imaging

Organelles play pivotal roles in preserving cell structure and function, and any disruption can result in cellular dysfunction and eventual cell death.<sup>62</sup> Achieving precise targeting of PSs to organelles offers several advantages, including the potential to lower PS dosages, mitigate side effects, reduce the risk of drug resistance, and enhance the effectiveness of PDT.<sup>11</sup> Indeed, given that ROS typically have an exceedingly brief lifetime and a limited diffusion range in biological systems,<sup>63</sup> PSs designed to precisely target organelles often exhibit superior PDT outcomes.<sup>64</sup> In this context, a number of organelle-specific PSs already have been reported with localization to the nuclei,<sup>31,41,65–67</sup> mitochondria,<sup>20,68–70</sup> multivesicular bodies,<sup>55</sup> lysosomes<sup>19,71–74</sup> and endoplasmic reticulum (ER).<sup>75–79</sup>

Next, we thus investigated if the high fluorescence emission demonstrated by these new PSs could be used to probe their cellular emission fingerprint by confocal laser scanning microscopy (CLSM). Live HeLa cells were treated with **DBXI** or **DBAI** at a concentration of 500 nM, followed by a 24-hour incubation.





Fig. 5 Cellular co-localization of **DBXI** and **DBAI** with ER tracker. CLSM images of live HeLa cells treated with **DBXI** (500 nM, green signal) (A) or **DBAI** (500 nM, green signal) (B) and incubated for 24 hours. After 24 hours, HeLa cells were co-stained with the nuclear dye Hoechst 33342 (500 nM, blue signal) and ER-Tracker Red (500 nM, red signal). 2D scatter diagrams depicting **DBXI** or **DBAI** and ER-Tracker Red channels are presented, and the quantification of colocalization has been accomplished using PCC. Image settings:  $\lambda_{\text{exc}}/\lambda_{\text{em}}$ : 405/420–470 nm for Hoechst;  $\lambda_{\text{exc}}/\lambda_{\text{em}}$ : 480/495–560 nm for **DBXI** or **DBAI**;  $\lambda_{\text{exc}}/\lambda_{\text{em}}$ : 587/600–710 nm for ER-Tracker Red. The scale bar is set at 25  $\mu\text{m}$  for regular images and 10  $\mu\text{m}$  for the enlarged images.



The incubation time was carefully selected based on the results of phototoxicity experiments (detailed below) to coincide precisely with the period during which light is applied to induce cell death. This synchronization ensures consistent PS accumulation and distribution within cellular compartments, thereby avoiding variability in PS concentration and localization that could affect the interpretation of the experimental outcomes. This treatment initially revealed an accumulation of the PSs in the cytoplasm, confirming that the molecules were well dissolved within the cellular environment and isolated as highly emissive species (Fig. 4–6). Thereafter, the intracellular distribution of the PSs was further explored by using four different commercially available organelle-selective live-cell trackers, namely Hoechst 33342, ER-Tracker Red, Lyso-Tracker Red, and Mito-Tracker Red to specifically label the nuclei, ER, lysosomes, and mitochondria, respectively. No relevant nuclear colocalization was observed between the PSs and Hoechst 33342, suggesting negligible uptake in the nucleus (Fig. 4–6). Also, low to moderate Pearson's correlation coefficients (PCC) were observed between the PSs and Lyso-Tracker Red, indicating their limited accumulation within the lysosomes (Fig. 4).

On the other hand, and as depicted in Fig. 5, the green fluorescence of **DBXI** and **DBAI** exhibited significant overlap with the fluorescence of ER-Tracker Red, yielding PCC values of 0.59 and 0.82 for **DBXI** and **DBAI**, respectively whereas the degree of colocalization between **DBXI** or **DBAI** and Mito-Tracker Red was lower, with PCC values of 0.3 and 0.61 for **DBXI** and **DBAI**, respectively (as seen in Fig. 6). These results highlight a good extent of PS internalization within the ER. Moreover, it is noteworthy that **DBXI** exhibited distinct, intense fluorescent clusters with a punctate nature in the cytoplasm, which did not overlap with the signals emitted by any of the organelle-specific trackers employed, suggesting further accumulation into vesicular bodies (Fig. 4–6). Indeed, the PCC value of 0.59 calculated for the co-localization of **DBXI** and ER-Tracker Red would be expected to be higher if the punctate signal of **DBXI** were excluded from the analysis. We believe that the slight differences in the staining patterns observed for **DBXI** and **DBAI** can be partially attributed to their differing hydrophobic properties. **DBAI**, which is fairly soluble, predominantly demonstrated uniform accumulation in the ER. In contrast, **DBXI**, due to its higher hydrophobicity, also tended to accumulate in vesicles with likely lipophilic character. These



**Fig. 6** Cellular localization of **DBXI** and **DBAI**. CLSM images of live HeLa cells treated with **DBXI** (500 nM, green signal) (A) or **DBAI** (500 nM, green signal) (B) and incubated for 24 hours. After 24 hours, cells were co-stained with the nuclear dye Hoechst 33342 (500 nM, blue signal) and Mito-Tracker Red (100 nM, red signal). 2D scatter diagrams depicting **DBXI** or **DBAI** and Mito-Tracker Red channels are presented, and the quantification of colocalization has been accomplished using PCC. Image settings:  $\lambda_{\text{exc}}/\lambda_{\text{em}}$ : 405/420–470 nm for Hoechst;  $\lambda_{\text{exc}}/\lambda_{\text{em}}$ : 480/495–560 nm for **DBXI** or **DBAI**;  $\lambda_{\text{exc}}/\lambda_{\text{em}}$ : 580/590–715 nm for Mito-Tracker Red. The scale bar is set at 25  $\mu\text{m}$  for regular images and 10  $\mu\text{m}$  for the enlarged images.



nanometer-sized spherical organelles may correspond to multi-vesicular bodies (MVBs) containing membrane-bound intraluminal vesicles (ILVs) or lipid droplets (LDs).


Targeting the ER holds significant importance in PDT and a number of PSs have been designed to accumulate in this organelle.<sup>11</sup> The ER forms a complex network of membranes throughout the cytoplasm, interacting thereby closely with other organelles. It plays a vital role in several cellular processes, including lipid and protein synthesis, and the

maintenance of calcium homeostasis.<sup>70–80</sup> Hence, during the PDT treatment, the production of ROS within the ER can induce localized stress resulting in an elevation of intracellular calcium levels and an enhanced expression of specific proteins.<sup>81,82</sup> If left unrepaired, this stress can ultimately lead to programmed cell death through apoptosis or necrosis.<sup>83–85</sup> As a result, the ER has thus emerged as a promising therapeutic target in the context of anti-tumor strategies and addressing this organelle with our PSs is anticipated to substantially strengthen the efficacy of PDT.


### *In cellulo* ROS generation and PDT activity

The ability of PSs to generate ROS was evaluated and tested in live HeLa cells using the CellROX™ green reagent (Fig. 7). CellROX™ functions as a DNA fluorescent probe to identify oxidative stress within the nuclei of living cells. In its reduced state, the dye exhibits minimal fluorescence. However, upon ROS-induced oxidation, it binds to DNA in both the nuclei and mitochondria, emitting intense green fluorescence.<sup>55</sup> Our findings confirm that both **DBXI** or **DBAI** significantly increased intracellular ROS production, as evidenced by the robust green fluorescence observed in the nuclei of HeLa cells under continuous irradiation with a 480 nm supercontinuum white light laser (WLL) for 5 minutes (Fig. 7). Crucially, in control experiments involving the CellROX™ green reagent conducted without PSs or light, no nuclear fluorescent signals associated with ROS were observed (Fig. 7), confirming that the intracellular ROS generation is specifically triggered in PS-treated cells under light irradiation, thus reinforcing the potential value of these PSs for targeted applications.

Motivated by the compelling body of evidence gathered from both *in vitro* (test tube) and cell-based experiments, which attested to the PSs' remarkable capacity for ROS generation, we turned our attention to a comprehensive evaluation of their potential phototoxic effects. To evaluate the potential phototoxic effects of such new PSs, PrestoBlue cell viability assay was




**Fig. 7** Intracellular ROS Detection. Live HeLa cells were treated with **DBXI** (500 nM) (A), **DBAI** (500 nM) (B), or DMSO (0.04% v/v) (C), and incubated for 24 hours. Subsequently, CellROX™ green reagent (5  $\mu$ M) and Hoechst 33258 (500 nM) were introduced to the cells and allowed to incubate for 30 minutes at 37 °C. Finally, the cells were imaged after irradiation with a 480 nm supercontinuum white light laser (WLL) for 0 or 5 minutes. The PS-mediated production of ROS, as indicated by the activation of the nuclear fluorescence signal of CellROX™, is highlighted for some cells by the white circles. The green fluorescent signal in the cytoplasm originates from the excitation of the PSs. Control experiments with DMSO demonstrated the absence of any signal interference from CellROX™. Image settings:  $\lambda_{exc}/\lambda_{em}$ : 405/415–450 nm for Hoechst;  $\lambda_{exc}/\lambda_{em}$ : 480/495–675 nm for CellROX™. Scale bar 20  $\mu$ m.



**Fig. 8** Phototoxicity studies in HeLa cells. Cell viability assay performed in the absence (A) and (B) or presence (C) and (D) of blue light (27 mW cm<sup>-2</sup>) irradiated for 6 min at different **DBXI** or **DBAI** concentrations. The error bars represent the mean  $\pm$  standard deviation ( $n = 3$ ).






**Scheme 2** Chemical structures,  $\Phi_F$ ,  $\Phi_\Delta$ , and  $IC_{50}$  (HeLa cells) values for **DBXI** and **DBAI** from this study, along with their closely related published analogs **BTI**, **T1**, **T2**, **T3**, and **DBI**, tested under similar experimental conditions. **BTI** features a planar structure with highly emissive properties but not detectable  $^1O_2$ . The phototoxicity of **BTI** likely occurs via a type-I mechanism involving superoxide species.<sup>24</sup> In contrast, the ISC in **T1**, **T2**, and **T3** is facilitated by a thionation strategy, which significantly influences their emissive properties.<sup>24</sup> **DBI** is characterized by a highly  $\pi$ -distorted skeleton that enhances ISC but markedly reduces its fluorescence.<sup>55</sup> Replacing the sulfur atom in **DBI** with an oxygen atom (**DBXI**) or an unsubstituted amine (**DBAI**) achieves an optimal balance between optical properties and phototherapeutic activity. Not determined parameters due to the near absence of signal are marked as N.D.

carried out.<sup>55,86,87</sup> This assay serves as a valuable tool for assessing if these drugs impact cell viability. Consequently, HeLa cells were first cultured with different concentrations (0–25  $\mu$ M) of PSs in the absence of light for a duration of 48 hours. Notably, the cell viability remained consistently high during

this period, suggesting the absence of significant dark cytotoxic effects (Fig. 8(A) and (B)). Next, to perform the photoirradiation analysis, the cells were exposed to varying PS concentrations (0–1.56  $\mu$ M) for 24 hours, followed by a 6-minute irradiation under a blue LED light cube (470/22 nm) prior to be further incubated



**Fig. 9** Time-lapse experiments were conducted to study light-induced morphological alterations in HeLa cells treated with **DBXI** or **DBAI** (1  $\mu$ M). Images were taken at intervals of 0, 6 and 12 minutes after exposure to blue light (30  $mW\ cm^{-2}$ ). Control experiments were carried out using HeLa cells treated with DMSO. Black arrows aim to show the appearance of apoptotic bodies. Scale bar 100  $\mu$ m.



for an additional 24 hours. These experimental parameters were carefully optimized to avoid cell death due to excessive light exposure on the one hand, and to match the incubation time and overall experimental conditions employed in the dark cytotoxicity assessments on the other. As shown in Fig. 8(C) and (D), the PSs efficiently inhibited cell proliferation in a dose-dependent manner, exhibiting  $IC_{50}$  values of approximately 100 nM ( $IC_{50}(\text{DBXI}) = 96.4 \pm 26.4$  nM and  $IC_{50}(\text{DBAI}) = 103.2 \pm 15.0$  nM). It is worth noting that these  $IC_{50}$  values are among the most potent documented organic PSs and within the highest reported for ER-specific PSs.<sup>11,24,55</sup> Additionally, the phototherapeutic index ( $PI = IC_{50}(\text{dark})/IC_{50}(\text{light})$ ) of both compounds is at least greater than 240, establishing these compounds as very efficient PSs and far more efficient than the majority of PSs incorporating heavy atoms.

The photocytotoxic activity of **DBXI** and **DBAI** is particularly noteworthy, considering that most uncharged PSs tend to form molecular aggregates in aqueous solutions, which can adversely affect their emissive properties and the efficacy of PDT.<sup>32,88–91</sup> Research, conducted by us and others, has shown that biomolecules such as proteins,<sup>24,89–93</sup> nucleic acids,<sup>87,94–99</sup> and lipids<sup>100–105</sup> can disassemble self-assembled dyes, restoring both their  $\Phi_F$  and  $\Phi_A$ .<sup>106</sup> This disassembly ensures that even if **DBXI** and **DBAI** form aggregates, they will become active and detectable at nanomolar concentrations in cellular environments. Furthermore, a direct comparison of  $\Phi_F$  and  $\Phi_A$ , along with  $IC_{50}$  values from HeLa cells for **DBXI** and **DBAI**, against structurally related analogs such as **DBI**,<sup>55</sup> **BTI**,<sup>24</sup> and its thionated variants (**T1**, **T2**, and **T3**),<sup>24</sup> highlights the significant improvements made to these compounds to achieve theranostic outcomes (Scheme 2).

Finally, time-lapse microscopy experiments were conducted to observe the effects of the treatment on cell morphology. In stark contrast to control cells, HeLa cells treated with PSs exhibited noticeable alterations in morphology when subjected to continuous irradiation with blue LED light for up to 12

minutes. These alterations included characteristic signs of late-stage apoptosis, such as plasma membrane blebbing and potential nuclear enlargement, which align well with previously reported analogues (Fig. 9).<sup>20,24,55</sup>


These results indicate that exposing cells loaded with **DBAI** and **DBXI** to light irradiation leads to significant cytotoxicity through the generation of ROS, severely disrupting cellular functions and causing cell death. This effect, particularly with **DBXI**, was further validated by the live/dead viability/cytotoxicity staining assay. Fig. 10 shows that only the HeLa cells treated with **DBXI** and subjected to light irradiation exhibited a bright red signal, signifying cell death due to plasma membrane rupture.

## 4. Conclusions

Highlighting the pivotal role of structural innovation, our research leverages and generalizes a twisted  $\pi$ -conjugated system strategy, marking significant advancements in fine-tuning the efficiency of ROS generation and fluorescence emission in PSs. This was achieved through controlled chemical modification of the dibenzothioxanthene imide scaffold, employing either a less bulky chalcogen oxygen or an unsubstituted amine. The outcome was the synthesis of two unique heavy-atom-free  $\pi$ -distorted PSs, each characterized by their mechanism of action and targeted ability towards the ER. Their notable capacity to activate both type-I and/or type-II photodynamic mechanisms, alongside maintaining high fluorescence emission levels, sets them apart from the majority of other PS reported in the literature. This dual functionality not only facilitates precise tracking of their distribution within live cells at nanomolar concentrations but also enables the induction of phototoxic effects at exceptionally low concentrations, with negligible dark toxicity. Through this work, we demonstrate the transformative potential of strategic structural design in surmounting the existing barriers in PDT, paving the way for future theranostic innovations with a special emphasis on shifting the optical properties to the near infra-red region.

## Author contributions

D. P. S., K. M. and M. G. M. synthesized and characterized the new PSs. P. J., F. G., and P. B. were involved in the supervision and discussion of the synthetic procedures. L. K. carried out EPR measurements, C. M. all photophysical characterizations and T. L. B. the computational analyses. M. A. characterized and solved the X-ray structures of the two PSs in addition to registering their CCDC numbers. Y. Z. and C. C. designed the new molecule from a synthetic point of view. N. S. was involved in the supervision and discussion of the biological data. M. D. designed and carried out biological experiments, analyzed and interpreted biological data and wrote and revised the manuscript with the contribution of N. S. C. M. and C. C.



**Fig. 10** The viability of HeLa cells was assessed using the LIVE/DEAD™ assay. The cells were treated with **DBXI** (500 nM) or an equivalent volume of DMSO and incubated at 37 °C for 24 hours. Where noted, blue light exposure was administered at an intensity of 30 mW cm<sup>-2</sup> for 6 minutes, succeeded by another 24-hour incubation period at 37 °C. For detecting cytotoxicity, LIVE/DEAD™ fixable red stain (1  $\mu\text{L mL}^{-1}$ ) was applied to the cells for 30 minutes at 37 °C prior to fixation with PFA. The stain's excitation/emission wavelengths were set at 598/630–730 nm. Scale bar 50  $\mu\text{m}$ .



## Data availability

The data supporting this article have been included as part of the ESI.†

## Conflicts of interest

A patent application covering the technology presented in this manuscript has been filed.

## Acknowledgements

M. Deiana would like to acknowledge financial support from project no. 2022/47/P/NZ5/01156, which is co-funded by the National Science Centre and the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 945339. M. Deiana also thanks the Swedish Cancer Society for providing financial support through the postdoctoral fellowship (21 0302 PT 01 H). D. Puchán Sánchez and K. Morice acknowledge the MITI of the CNRS and the ANR (BTXI-Apogee, ANR-20-CE05-0029), respectively for their PhD grants. T. Le Bahers acknowledges the Institut Universitaire de France for funding and the SYSPROD project and AXELERA Pôle de Compétitivité for financial support (PSMN Data Center). M. Deiana and N. Sabouri acknowledge the Biochemical Imaging Center at Umeå University and the National Microscopy Infrastructure, NMI (VR-RFI 2019-00217) for providing assistance in microscopy, and the Chemical Biology Consortium Sweden (CBCS) at Umeå University for access to the Synergy H4 microplate reader. Work in N. Sabouri lab received support from the Swedish Cancer Society (22 2380 Pj 01 H), the Swedish Research Council (VR-MH 2021-02468), Knut and Alice Wallenberg foundations (KAW 2021.0173), and Biotechnology grant from the Medical faculty at Umeå University. This study received the support of the EUR LUMOMAT (programme Investissements d'Avenir ANR-18-EURE-0012) through the grant of P. Josse (Project AZA BTXI).

## Notes and references

- B. M. Vickerman, E. M. Zywot, T. K. Tarrant and D. S. Lawrence, *Nat. Rev. Chem.*, 2021, **1**, 1–19.
- K. Hüll, J. Morstein and D. Trauner, *Chem. Rev.*, 2018, **118**, 10710–10747.
- P. Kobauri, F. J. Dekker, W. Szymanski and B. L. Feringa, *Angew. Chem., Int. Ed.*, 2023, **62**, e202300681.
- P. Cheng and K. Pu, *ACS Appl. Mater. Interfaces*, 2020, **12**, 5286–5299.
- X. Li, J. F. Lovell, J. Yoon and X. Chen, *Nat. Rev. Clin. Oncol.*, 2020, **17**, 657–674.
- T. Mishchenko, I. Balalaeva, A. Gorokhova, M. Vedunova and D. V. Krysko, *Cell Death Dis.*, 2022, **13**, 455.
- H. Huang, S. Banerjee, K. Qiu, P. Zhang, O. Blacque, T. Malcomson, M. J. Paterson, G. J. Clarkson, M. Staniforth, V. G. Stavros, G. Gasser, H. Chao and P. J. Sadler, *Nat. Chem.*, 2019, **11**, 1041–1048.
- J. An, S. Tang, G. Hong, W. Chen, M. Chen, J. Song, Z. Li, X. Peng, F. Song and W.-H. Zheng, *Nat. Commun.*, 2022, **13**, 2225.
- K.-X. Teng, L.-Y. Niu, N. Xie and Q.-Z. Yang, *Nat. Commun.*, 2022, **13**, 6179.
- J. Yan, T. Gao, Z. Lu, J. Yin, Y. Zhang and R. Pei, *ACS Appl. Mater. Interfaces*, 2021, **13**, 27749–27773.
- R. Wang, X. Li and J. Yoon, *ACS Appl. Mater. Interfaces*, 2021, **13**, 19543–19571.
- T. C. Pham, V.-N. Nguyen, Y. Choi, S. Lee and J. Yoon, *Chem. Rev.*, 2021, **121**, 13454–13619.
- X. Zhao, J. Liu, J. Fan, H. Chao and X. Peng, *Chem. Soc. Rev.*, 2021, **50**, 4185–4219.
- C. Mu, W. Wang, J. Wang, C. Gong, D. Zhang and X. Zhang, *Angew. Chem., Int. Ed.*, 2020, **59**, 21515–21519.
- V.-N. Nguyen, Y. Yan, J. Zhao and J. Yoon, *Acc. Chem. Res.*, 2021, **54**, 207–220.
- S. Monro, K. L. Colón, H. Yin, J. Roque, III, P. Konda, S. Gujjar, R. P. Thummel, L. Lilge, C. G. Cameron and S. A. McFarland, *Chem. Rev.*, 2019, **119**, 797–828.
- M. Lan, S. Zhao, W. Liu, C.-S. Lee, W. Zhang and P. Wang, *Adv. Healthcare Mater.*, 2019, **8**, 1900132.
- M. A. Filatov, *Org. Biomol. Chem.*, 2020, **18**, 10–27.
- G. He, N. Xu, H. Ge, Y. Lu, R. Wang, H. Wang, J. Du, J. Fan, W. Sun and X. Peng, *ACS Appl. Mater. Interfaces*, 2021, **13**, 19572–19580.
- J. Miao, Y. Huo, G. Yao, Y. Feng, J. Weng, W. Zhao and W. Guo, *Angew. Chem., Int. Ed.*, 2022, **61**, e202201815.
- X. Zhang, Z. Wang, Y. Hou, Y. Yan, J. Zhao and B. Dick, *J. Mater. Chem. C*, 2021, **9**, 11944–11973.
- M. A. Filatov, S. Karuthedath, P. M. Polestshuk, H. Savoie, K. J. Flanagan, C. Sy, E. Sitte, M. Telitchko, F. Laquai, R. W. Boyle and M. O. Senge, *J. Am. Chem. Soc.*, 2017, **139**, 6282–6285.
- M. Lv, Y. Yu, M. E. Sandoval-Salinas, J. Xu, Z. Lei, D. Casanova, Y. Yang and J. Chen, *Angew. Chem., Int. Ed.*, 2020, **59**, 22179–22184.
- M. Deiana, P. Josse, C. Dalinot, A. Osmolovskiy, P. S. Marqués, J. M. A. Castán, L. Abad Galán, M. Allain, L. Khrouz, O. Maury, T. Le Bahers, P. Blanchard, S. Dabos-Seignon, C. Monnereau, N. Sabouri and C. Cabanetos, *Commun. Chem.*, 2022, **5**, 142.
- Y. Hou, Q. Liu and J. Zhao, *Chem. Commun.*, 2020, **56**, 1721–1724.
- Y. Xiao, X. Huang, J. Feng, Z. Ni, L. Gai, X. Xiao, X. Sui and H. Lu, *Dyes Pigm.*, 2022, **200**, 110167.
- H. Liang, M. Lu, Z. Mahmood, Z. Li, Z. Chen, G. Chen, M.-D. Li, Y. Huo and S. Ji, *Angew. Chem., Int. Ed.*, 2023, **62**, e202312600.
- W. Hu, M. Liu, X.-F. Zhang, M. Shi, M. Jia, X. Hu, L. Liu and T. Wang, *J. Mater. Chem. C*, 2020, **124**, 23558–23566.
- J. Tang, L. Wang, A. Loreda, C. Cole and H. Xiao, *Chem. Sci.*, 2020, **11**, 6701–6708.



- 30 X. Zhao, Q. Yao, S. Long, W. Chi, Y. Yang, D. Tan, X. Liu, H. Huang, W. Sun, J. Du, J. Fan and X. Peng, *J. Am. Chem. Soc.*, 2021, **143**, 12345–12354.
- 31 T. C. Pham, T. T. H. Hoang, D. N. Tran, G. Kim, T. V. Nguyen, T. V. Pham, S. Nandanwar, D. L. Tran, M. Park and S. Lee, *ACS Appl. Mater. Interfaces*, 2023, **15**, 47969–47977.
- 32 V.-N. Nguyen, S. Qi, S. Kim, N. Kwon, G. Kim, Y. Yim, S. Park and J. Yoon, *J. Am. Chem. Soc.*, 2019, **141**, 16243–16248.
- 33 Y. Dong, A. A. Sukhanov, J. Zhao, A. Elmali, X. Li, B. Dick, A. Karatay and V. K. Voronkova, *J. Mater. Chem. C*, 2019, **123**, 22793–22811.
- 34 S. Callaghan, M. A. Filatov, H. Savoie, R. W. Boyle and M. O. Senge, *Photochem. Photobiol. Sci.*, 2019, **18**, 495–504.
- 35 Y.-L. Lee, Y.-T. Chou, B.-K. Su, C.-C. Wu, C.-H. Wang, K.-H. Chang, J.-A. A. Ho and P.-T. Chou, *J. Am. Chem. Soc.*, 2022, **144**, 17249–17260.
- 36 Z. Wang, M. Ivanov, Y. Gao, L. Bussotti, P. Foggi, H. Zhang, N. Russo, B. Dick, J. Zhao, M. Di Donato, G. Mazzone, L. Luo and M. Fedin, *Chem. – Eur. J.*, 2020, **26**, 1091–1102.
- 37 T. C. Pham, S. Heo, V.-N. Nguyen, M. W. Lee, J. Yoon and S. Lee, *ACS Appl. Mater. Interfaces*, 2021, **13**, 13949–13957.
- 38 M. Pollum, S. Jockusch and C. E. Crespo-Hernández, *J. Am. Chem. Soc.*, 2014, **136**, 17930–17933.
- 39 P. Zhang, H. Kuang, Y. Xu, L. Shi, W. Cao, K. Zhu, L. Xu and J. Ma, *ACS Appl. Mater. Interfaces*, 2020, **12**, 42551–42557.
- 40 X. Yang, X. Zhang, Z. Yang, L. Cheng, X. Liu, S. Cao, H. Yue, Y. Cao, K.-N. Wang and Y. Zhang, *ACS Appl. Mater. Interfaces*, 2024, **16**, 9816–9825.
- 41 K.-N. Wang, L.-Y. Liu, D. Mao, M.-X. Hou, C.-P. Tan, Z.-W. Mao and B. Liu, *Angew. Chem., Int. Ed.*, 2022, **61**, e202114600.
- 42 Y. Zhang, L. Pang, C. Ma, Q. Tu, R. Zhang, E. Saeed, A. E. Mahmoud and J. Wang, *Anal. Chem.*, 2014, **86**, 3092–3099.
- 43 Y. Tang, X. Wang, G. Zhu, Z. Liu, X.-M. Chen, H. K. Bisoyi, X. Chen, X. Chen, Y. Xu, J. Li and Q. Li, *Small*, 2023, **19**, 2205440.
- 44 F. Hu, D. Mao, Kenry, X. Cai, W. Wu, D. Kong and B. Liu, *Angew. Chem., Int. Ed.*, 2018, **57**, 10182–10186.
- 45 M. M. Kim and A. Darafsheh, *Photochem. Photobiol.*, 2020, **96**, 280–294.
- 46 E. B. da Silva, M. W. M. Vasquez, B. C. de Almeida Teixeira, M. C. Neto, F. Sprenger, J. L. N. Filho, L. Almeida-Lopes and R. Ramina, *Acta Neurochir.*, 2024, **166**, 212.
- 47 P. Sarbadhikary, B. P. George and H. Abrahamse, *Theranostics*, 2021, **11**, 9054–9088.
- 48 Y. Wu, Y. Zhen, Y. Ma, R. Zheng, Z. Wang and H. Fu, *J. Phys. Chem. Lett.*, 2010, **1**, 2499–2502.
- 49 D. Reger, P. Haines, F. W. Heinemann, D. M. Guldi and N. Jux, *Angew. Chem., Int. Ed.*, 2018, **57**, 5938–5942.
- 50 K. Nagarajan, A. R. Mallia, K. Muraleedharan and M. Hariharan, *Chem. Sci.*, 2017, **8**, 1776–1782.
- 51 Y. Dong, B. Dick and J. Zhao, *Org. Lett.*, 2020, **22**, 5535–5539.
- 52 Z. Wang, L. Huang, Y. Yan, A. M. El-Zohry, A. Toffoletti, J. Zhao, A. Barbon, B. Dick, O. F. Mohammed and G. Han, *Angew. Chem., Int. Ed.*, 2020, **59**, 16114–16121.
- 53 Y. Dong, P. Kumar, P. Maity, I. Kurganskii, S. Li, A. Elmali, J. Zhao, D. Escudero, H. Wu, A. Karatay, O. F. Mohammed and M. Fedin, *Phys. Chem. Chem. Phys.*, 2021, **23**, 8641–8652.
- 54 X. Xiao, K. Ye, M. Imran and J. Zhao, *Appl. Sci.*, 2022, **12**, 9933–9953.
- 55 M. Deiana, J. M. Andrés Castán, P. Josse, A. Kahsay, D. P. Sánchez, K. Morice, N. Gillet, R. Ravindranath, A. K. Patel, P. Sengupta, I. Obi, E. Rodriguez-Marquez, L. Khrouz, E. Dumont, L. Abad Galán, M. Allain, B. Walker, H. S. Ahn, O. Maury, P. Blanchard, T. Le Bahers, D. Öhlund, J. von Hofsten, C. Monnereau, C. Cabanetos and N. Sabouri, *Nucleic Acids Res.*, 2023, **51**, 6264–6285.
- 56 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman and D. J. Fox, *Gaussian 09*, Gaussian Inc., Wallingford CT, 2016.
- 57 C. Adamo and V. Barone, *J. Chem. Phys.*, 1999, **110**, 6158–6170.
- 58 J. Tomasi, B. Mennucci and R. Cammi, *Chem. Rev.*, 2005, **105**, 2999–3094.
- 59 F. Neese, F. Wennmohs, U. Becker and C. Riplinger, *J. Chem. Phys.*, 2020, **152**, 224108.
- 60 T. Le Bahers, C. Adamo and I. Ciofini, *J. Chem. Theory Comput.*, 2011, **7**, 2498–2506.
- 61 C. Adamo, T. Le Bahers, M. Savarese, L. Wilbraham, G. García, R. Fukuda, M. Ehara, N. Rega and I. Ciofini, *Coord. Chem. Rev.*, 2015, **304–305**, 166–178.
- 62 J. Yang, A. Griffin, Z. Qiang and J. Ren, *Signal Transduction Targeted Ther.*, 2022, **7**, 379.
- 63 P. R. Ogilby, *Chem. Soc. Rev.*, 2010, **39**, 3181–3209.
- 64 W. Fan, P. Huang and X. Chen, *Chem. Soc. Rev.*, 2016, **45**, 6488–6519.
- 65 Z. Yu, W. Pan, N. Li and B. Tang, *Chem. Sci.*, 2016, **7**, 4237–4244.
- 66 P. Zhang, H. Huang, S. Banerjee, G. J. Clarkson, C. Ge, C. Imberti and P. J. Sadler, *Angew. Chem., Int. Ed.*, 2019, **58**, 2350–2354.



- 67 Y. Yang, W. Zhu, L. Feng, Y. Chao, X. Yi, Z. Dong, K. Yang, W. Tan, Z. Liu and M. Chen, *Nano Lett.*, 2018, **18**, 6867–6875.
- 68 Y. Wang, S. Xu, L. Shi, C. Teh, G. Qi and B. Liu, *Angew. Chem., Int. Ed.*, 2021, **60**, 14945–14953.
- 69 S. Chakraborty, B. K. Agrawalla, A. Stumper, N. M. Vegi, S. Fischer, C. Reichardt, M. Kögler, B. Dietzek, M. Feuring-Buske, C. Buske, S. Rau and T. Weil, *J. Am. Chem. Soc.*, 2017, **139**, 2512–2519.
- 70 W. Lv, Z. Zhang, K. Y. Zhang, H. Yang, S. Liu, A. Xu, S. Guo, Q. Zhao and W. Huang, *Angew. Chem., Int. Ed.*, 2016, **55**, 9947–9951.
- 71 H. Huang, B. Yu, P. Zhang, J. Huang, Y. Chen, G. Gasser, L. Ji and H. Chao, *Angew. Chem., Int. Ed.*, 2015, **54**, 14049–14052.
- 72 Y. Tu, W. Xia, X. Wu and L. Wang, *Org. Biomol. Chem.*, 2021, **19**, 6098–6107.
- 73 N. Niu, H. Zhou, N. Liu, H. Jiang, E. Hussain, Z. Hu and C. Yu, *Chem. Commun.*, 2019, **55**, 1036–1039.
- 74 Z. Zhou, J. Liu, J. Huang, T. W. Rees, Y. Wang, H. Wang, X. Li, H. Chao and P. J. Stang, *Proc. Natl. Acad. Sci. U. S. A.*, 2019, **116**, 20296–20302.
- 75 S. Li, Y. Chen, Y. Wu, S. Yao, H. Yuan, Y. Tan, F. Qi, W. He and Z. Guo, *Chem. – Eur. J.*, 2022, **28**, e202202680.
- 76 B. Yuan, J. Liu, R. Guan, C. Jin, L. Ji and H. Chao, *Dalton Trans.*, 2019, **48**, 6408–6415.
- 77 H. Ma, Y. Lu, Z. Huang, S. Long, J. Cao, Z. Zhang, X. Zhou, C. Shi, W. Sun, J. Du, J. Fan and X. Peng, *J. Am. Chem. Soc.*, 2022, **144**, 3477–3486.
- 78 J. S. Nam, M.-G. Kang, J. Kang, S.-Y. Park, S. J. C. Lee, H.-T. Kim, J. K. Seo, O.-H. Kwon, M. H. Lim, H.-W. Rhee and T.-H. Kwon, *J. Am. Chem. Soc.*, 2016, **138**, 10968–10977.
- 79 H. Deng, Z. Zhou, W. Yang, L.-S. Lin, S. Wang, G. Niu, J. Song and X. Chen, *Nano Lett.*, 2020, **20**, 1928–1933.
- 80 A. Spang, *Curr. Opin. Cell Biol.*, 2018, **53**, 92–96.
- 81 D. S. Schwarz and M. D. Blower, *Cell. Mol. Life Sci.*, 2016, **73**, 79–94.
- 82 A. Raffaello, C. Mammucari, G. Gherardi and R. Rizzuto, *Trends Biochem. Sci.*, 2016, **41**, 1035–1049.
- 83 J.-C. Simard, I. Durocher and D. Girard, *Apoptosis*, 2016, **21**, 1279–1290.
- 84 M. Wang and R. J. Kaufman, *Nat. Rev. Cancer*, 2014, **14**, 581–597.
- 85 T. Verfaillie, A. D. Garg and P. Agostinis, *Cancer Lett.*, 2013, **332**, 249–264.
- 86 J. Jamroskovic, M. Doimo, K. Chand, I. Obi, R. Kumar, K. Brännström, M. Hedenström, R. Nath Das, A. Akhunzianov, M. Deiana, K. Kasho, S. Sulis Sato, P. L. Pourbozorgi, J. E. Mason, P. Medini, D. Öhlund, S. Wanrooij, E. Chorell and N. Sabouri, *J. Am. Chem. Soc.*, 2020, **142**, 2876–2888.
- 87 M. Deiana, K. Chand, E. Chorell and N. Sabouri, *J. Phys. Chem. Lett.*, 2023, **14**, 1862–1869.
- 88 X. Li, S. Yu, Y. Lee, T. Guo, N. Kwon, D. Lee, S. C. Yeom, Y. Cho, G. Kim, J.-D. Huang, S. Choi, K. T. Nam and J. Yoon, *J. Am. Chem. Soc.*, 2019, **141**, 1366–1372.
- 89 X. Li, C. y Kim, S. Lee, D. Lee, H.-M. Chung, G. Kim, S.-H. Heo, C. Kim, K.-S. Hong and J. Yoon, *J. Am. Chem. Soc.*, 2017, **139**, 10880–10886.
- 90 D. Li, X.-Z. Wang, L.-F. Yang, S.-C. Li, Q.-Y. Hu, X. Li, B.-Y. Zheng, M.-R. Ke and J.-D. Huang, *ACS Appl. Mater. Interfaces*, 2019, **11**, 36435–36443.
- 91 H. Liu, L.-L. Lv, H. Wen, D.-M. Zhao, J. Wu, M.-R. Ke, B.-Y. Zheng, J. Li, X. Li and J.-D. Huang, *ACS Appl. Mater. Interfaces*, 2022, **14**, 28581–28590.
- 92 Z. Luo, T. Lv, K. Zhu, Y. Li, L. Wang, J. J. Gooding, G. Liu and B. Liu, *Angew. Chem., Int. Ed.*, 2020, **59**, 3131–3136.
- 93 L. Esteouille, F. Daubeuf, M. Collot, S. Riché, T. Durroux, D. Brasse, P. Marchand, J. Karpenko, A. S. Klymchenko and D. Bonnet, *Chem. Sci.*, 2020, **11**, 6824–6829.
- 94 X. Li, S. Yu, D. Lee, G. Kim, B. Lee, Y. Cho, B.-Y. Zheng, M.-R. Ke, J.-D. Huang, K. T. Nam, X. Chen and J. Yoon, *ACS Nano*, 2018, **12**, 681–688.
- 95 Z. Hu, D. Wang, Q. Zhou, J. Jie and H. Su, *J. Phys. Chem. B*, 2024, **128**, 576–584.
- 96 C. Okamoto, A. Momotake and Y. Yamamoto, *J. Phys. Chem. B*, 2023, **127**, 4514–4522.
- 97 M. Deiana, K. Chand, J. Jamroskovic, I. Obi, E. Chorell and N. Sabouri, *Angew. Chem., Int. Ed.*, 2020, **59**, 896–902.
- 98 M. Deiana, K. Chand, J. Jamroskovic, R. N. Das, I. Obi, E. Chorell and N. Sabouri, *Nanoscale*, 2020, **12**, 12950–12957.
- 99 V. Grande, C.-A. Shen, M. Deiana, M. Dudek, J. Olesiak-Banska, K. Matczyszyn and F. Würthner, *Chem. Sci.*, 2018, **9**, 8375–8381.
- 100 M. Collot, P. Ashokkumar, H. Anton, E. Boutant, O. Faklaris, T. Galli, Y. Mély, L. Danglot and A. S. Klymchenko, *Cell Chem. Biol.*, 2019, **26**, 600–614.
- 101 M. Collot, E. Boutant, M. Lehmann and A. S. Klymchenko, *Bioconjugate Chem.*, 2019, **30**, 192–199.
- 102 I. O. Aparin, R. Yan, R. Pelletier, A. A. Choi, D. I. Danylchuk, K. Xu and A. S. Klymchenko, *J. Am. Chem. Soc.*, 2022, **144**, 18043–18053.
- 103 F. Deng, L. Liu, Q. Qiao, C. Huang, L. Miao and Z. Xu, *Chem. Commun.*, 2019, **55**, 15045–15048.
- 104 M. Collot, T. K. Fam, P. Ashokkumar, O. Faklaris, T. Galli, L. Danglot and A. S. Klymchenko, *J. Am. Chem. Soc.*, 2018, **140**, 5401–5411.
- 105 K. Ohira, Y. Sato and S. Nishizawa, *ACS Sens.*, 2023, **8**, 522–526.
- 106 K. Saczuk, M. Dudek, K. Matczyszyn and M. Deiana, *Nanoscale Horiz.*, 2024, DOI: [10.1039/D4NH00186A](https://doi.org/10.1039/D4NH00186A).

